TB-500 and Thymosin Beta-4: A Research Overview
TB-500 is a name you will see on a lot of labels and in very few scientific papers. That is because it is a trade name, not a scientific term. This overview explains what analytical chemists actually found inside TB-500 products, how that relates to the larger protein thymosin beta-4, what the research covers, and where it currently stands. We keep it plain and we keep it sourced.
A trade name with a chemistry behind it
In 2012 two independent groups asked the same question: what is in a vial labelled TB-500? Both found a short peptide of seven amino acids, LKKTETQ, with an acetyl group attached to its first residue. That sequence is residues 17 to 23 of human thymosin beta-4, so the material is an N-acetylated fragment of the protein, written Ac-LKKTETQ (Esposito et al., 2012; Ho et al., 2012).
Here is the catch. The name is also used loosely for the whole thymosin beta-4 protein. WADA's list, for example, writes "thymosin-beta-4 and its derivatives, e.g. TB-500", and some animal studies simply call TB-500 synthetic thymosin beta-4. So when you read about TB-500, the first thing to check is which molecule the author means: the 43-residue protein or the 7-residue acetylated fragment.
Thymosin beta-4 and actin
Thymosin beta-4 is a 43-amino-acid protein found in cells throughout the body. Its best-understood job is to bind actin. Actin is the protein that cells assemble into filaments to hold their shape and to move. Thymosin beta-4 sequesters single actin units, which helps regulate how much actin is free to build filaments at any moment.
Within the protein, the LKKTETQ stretch is the central actin-binding site. Laboratory work has linked that region to cell migration and to angiogenesis, the growth of new blood vessels. A 2010 paper mapped several of thymosin beta-4's activities to short stretches of its sequence, and the actin-binding region was one of them (Sosne et al., 2010).
One point of confusion is worth clearing up. The same paper describes a different short fragment, Ac-SDKP, which is the first four residues at the other end of the protein and has its own literature on inflammation and fibrosis. Ac-SDKP is not TB-500, and findings about one should not be attributed to the other.
What TB-500 research actually looks at
The fragment-specific literature is small and leans heavily toward analytical chemistry. It falls into four areas.
- Anti-doping detection and metabolism. The largest share. Ho and colleagues developed a liquid chromatography and mass spectrometry method to detect TB-500 in equine urine and plasma. Esposito and colleagues synthesised and characterised the fragment so that testing labs would have a reference standard.
- Cell migration and wound-healing assays. Laboratory dishes in which cells are scratched or separated and the rate at which they close the gap is measured.
- The actin-binding region of thymosin beta-4. Structural and functional work on the LKKTETQ site within the parent protein.
- A rat tendon-repair model. A single study.
A 2024 paper brings the first two together. Rahaman and colleagues quantified TB-500 and its breakdown products in laboratory experiments and in rats using high-resolution mass spectrometry, then screened the fragment and its metabolites in a cell-based wound-healing assay (Rahaman et al., 2024). Notably, the authors stated that the biological effects of TB-500 itself had not been documented before their screen.
Does the fragment do what the whole protein does?
This is the open question, and the answer in the literature is: not established. The actin-binding region sits inside thymosin beta-4, and the parent protein's activities have been studied for decades. Whether a seven-residue acetylated piece of it reproduces those activities on its own is a different question, and it has been tested very little. The 2024 note that TB-500's biological effects had not been documented is the clearest statement of where the field was.
Practically, that means most of what is written about TB-500 online is borrowed from thymosin beta-4 research and applied to a fragment without the experiments to back the transfer.
Status
- Research stage: preclinical. Fragment-specific research is limited to laboratory, animal and anti-doping studies.
- WADA: thymosin beta-4 and its derivatives, with TB-500 named as the example, are prohibited under section S2.
- FDA compounding list: the entry "thymosin beta-4 fragment" appears among bulk substances that were nominated and later withdrawn.
How a TB-500 lot is characterised
Because the name is ambiguous, lot testing matters more here than for most compounds. The certificate should settle which molecule is in the vial.
Identity by mass spectrometry
Ac-LKKTETQ has a specific molecular mass, and it is far smaller than the 43-residue protein. Mass spectrometry (MS) reports the measured mass, so the certificate shows at a glance whether the material is the acetylated fragment. The acetyl group also shifts the mass by a fixed amount, which is how the modification is confirmed.
Purity by HPLC
High-performance liquid chromatography (HPLC) separates the main peptide from related impurities and reports a measured purity. We do not quote one figure for every vial. Each lot's certificate states its own measured purity and identity.
Lot number and date
The certificate lists the lot number, the test date and the methods used. The lot number should match the one printed on the vial.
Storage
TB-500 is supplied as a freeze-dried (lyophilised) powder. Store sealed vials cool, dry and away from light, and let a cold vial reach room temperature before opening. These are storage notes for the laboratory, not instructions for use.
TB-500 at a glance
| Item | Detail |
|---|---|
| Name | TB-500 (trade name) |
| Identified content | Ac-LKKTETQ, the N-acetylated residues 17 to 23 of thymosin beta-4 |
| Parent protein | Thymosin beta-4, 43 amino acids, actin-sequestering |
| Region | Central actin-binding site |
| Research areas | Anti-doping detection and metabolism; cell migration assays; actin-binding region; one rat tendon-repair study |
| Research stage | Preclinical |
| WADA | Prohibited, S2 (thymosin beta-4 and derivatives) |
| Format | Lyophilised powder, single vial |
TB-500 is also one half of our BPC-157 + TB-500 blend, where it is confirmed separately on the certificate.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Analytical studies of TB-500 products identified a seven-residue acetylated fragment of thymosin beta-4 (Ac-LKKTETQ). Thymosin beta-4 is the full 43-residue protein. The name TB-500 is sometimes used loosely for both, so check which one a source means.
What does LKKTETQ mean?
It is the one-letter sequence of residues 17 to 23 of thymosin beta-4: leucine, lysine, lysine, threonine, glutamate, threonine, glutamine. This stretch is the protein's central actin-binding site.
Is TB-500 prohibited in sport?
Yes. WADA lists thymosin beta-4 and its derivatives, naming TB-500 as the example, under section S2 of the Prohibited List.
How do I know a vial holds the fragment and not something else?
Read the certificate of analysis. Mass spectrometry reports a measured mass, which should match Ac-LKKTETQ, and HPLC reports the lot's measured purity. The lot number on the certificate should match the vial.
See it in the catalogue: TB-500.
For laboratory research use only. Products sold by Amino Party Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.